DK1261360T3 - Casein-afledte peptider og anvendelser deraf i behandling - Google Patents

Casein-afledte peptider og anvendelser deraf i behandling

Info

Publication number: DK1261360T3
Authority: DK; Denmark
Prior art keywords: peptides; casein; stimulating; derived; treatment
Prior art date: 2000-03-01

Application number

DK01908105.8T

Other languages

English (en)

Inventor

Zvi Sidelman

Original Assignee

Peptera Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-01

Filing date

2001-03-01

Publication date

2010-05-03

2001-03-01 Application filed by Peptera Pharmaceuticals Ltd filed Critical Peptera Pharmaceuticals Ltd

2010-05-03 Application granted granted Critical

2010-05-03 Publication of DK1261360T3 publication Critical patent/DK1261360T3/da

Links

102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
239000005018 casein Substances 0.000 title abstract 3
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 title abstract 3
235000021240 caseins Nutrition 0.000 title abstract 3
230000004936 stimulating effect Effects 0.000 abstract 3
208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
208000036142 Viral infection Diseases 0.000 abstract 1
210000000601 blood cell Anatomy 0.000 abstract 1
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
208000014951 hematologic disease Diseases 0.000 abstract 1
230000011132 hemopoiesis Effects 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1
235000013336 milk Nutrition 0.000 abstract 1
239000008267 milk Substances 0.000 abstract 1
210000004080 milk Anatomy 0.000 abstract 1
231100000252 nontoxic Toxicity 0.000 abstract 1
230000003000 nontoxic effect Effects 0.000 abstract 1
230000007170 pathology Effects 0.000 abstract 1
230000009385 viral infection Effects 0.000 abstract 1
230000003612 virological effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4732—Casein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Obesity (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Virology (AREA)
Wood Science & Technology (AREA)
Toxicology (AREA)
Biophysics (AREA)
Marine Sciences & Fisheries (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)

DK01908105.8T 2000-03-01 2001-03-01 Casein-afledte peptider og anvendelser deraf i behandling DK1261360T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IL13483000A IL134830A0 (en)	2000-03-01	2000-03-01	Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
PCT/IL2001/000198 WO2001064234A1 (en)	2000-03-01	2001-03-01	Casein derived peptides and uses thereof in therapy

Publications (1)

Publication Number	Publication Date
DK1261360T3 true DK1261360T3 (da)	2010-05-03

Family

ID=11073892

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01908105.8T DK1261360T3 (da)	2000-03-01	2001-03-01	Casein-afledte peptider og anvendelser deraf i behandling

Country Status (21)

Country	Link
US (6)	US20020147144A1 (da)
EP (1)	EP1261360B1 (da)
JP (1)	JP2003528827A (da)
KR (1)	KR20030025907A (da)
CN (1)	CN1427725A (da)
AT (1)	ATE451929T1 (da)
AU (1)	AU782662B2 (da)
BR (1)	BR0109027A (da)
CA (1)	CA2401550A1 (da)
CZ (1)	CZ20022915A3 (da)
DE (1)	DE60140794D1 (da)
DK (1)	DK1261360T3 (da)
EA (3)	EA005579B1 (da)
HU (1)	HUP0301003A3 (da)
IL (2)	IL134830A0 (da)
MX (1)	MXPA02008569A (da)
NO (1)	NO20024157L (da)
NZ (1)	NZ521016A (da)
PL (1)	PL361307A1 (da)
WO (1)	WO2001064234A1 (da)
ZA (1)	ZA200206842B (da)

Families Citing this family (145)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MXPA04001890A (es) *	2001-08-30	2004-06-18	Chay 13 Medical Res Group N V	Peptidos derivados de caseina y sus usos en terapia.
AU2003217337A1 (en) *	2002-02-06	2003-09-02	University Of North Carolina At Chapel Hill	High-throughput cell identification and isolation method and apparatus
EP1359157A1 (en) *	2002-04-29	2003-11-05	Société des Produits Nestlé S.A.	Metallo-proteinase inhibitory agent
KR101188292B1 (ko) *	2002-11-27	2012-10-09	디엠아이 바이오사이언시스, 인크	인산화 증가로 인한 질병 및 증상의 치료방법
GB0313892D0 (en) *	2003-06-16	2003-07-23	Hannah Res Inst	Control of lactation
CA2558155A1 (en) *	2004-03-01	2005-09-09	Zvi Sidelman	Casein derived peptides and therapeutic uses thereof
BRPI0509541A (pt)	2004-03-30	2007-09-18	Monsanto Technology Llc	métodos para controlar agentes patógenos de planta utilizando n-fosfonometilglicina
WO2005099724A2 (en) *	2004-04-13	2005-10-27	Parallel Solutions, Inc.	Functionalized water-soluble polyphosphazene and uses thereof as modifiers of biological agents
EP1811933B1 (en)	2004-09-28	2016-03-23	Atrium Medical Corporation	Barrier layer
US9012506B2 (en)	2004-09-28	2015-04-21	Atrium Medical Corporation	Cross-linked fatty acid-based biomaterials
US9000040B2 (en) *	2004-09-28	2015-04-07	Atrium Medical Corporation	Cross-linked fatty acid-based biomaterials
GB0423352D0 (en) *	2004-10-21	2004-11-24	Hannah Res Inst	"Control of mammary cell number"
CA2607155C (en) *	2005-05-02	2016-09-13	Mileutis Ltd.	Pharmaceutical compositions comprising casein derived peptides and methods of use thereof
ES2319475B1 (es) *	2005-06-08	2010-02-16	Consejo Superior Investig. Cientificas	Peptidos bioactivos identificados en hidrolizados enzimaticos de caseinas lacteas y procedimiento de obtencion.
US11266607B2 (en) *	2005-08-15	2022-03-08	AbbVie Pharmaceuticals GmbH	Process for the manufacture and use of pancreatin micropellet cores
US9278161B2 (en)	2005-09-28	2016-03-08	Atrium Medical Corporation	Tissue-separating fatty acid adhesion barrier
US9427423B2 (en)	2009-03-10	2016-08-30	Atrium Medical Corporation	Fatty-acid based particles
HUE031989T2 (en)	2005-10-04	2017-08-28	Soligenix Inc	New peptides for the treatment and prevention of immune-related disorders, including treatment and prevention of infection by modulation of natural immunity
US20080118525A1 (en) *	2006-10-04	2008-05-22	Oreola Donini	Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity
US20070086958A1 (en) *	2005-10-14	2007-04-19	Medafor, Incorporated	Formation of medically useful gels comprising microporous particles and methods of use
GB2436328A (en) *	2006-03-22	2007-09-26	Regen Therapeutics Plc	Peptide derived from colostrinin
EP1836906B1 (en) *	2006-03-24	2009-07-01	Unilever N.V.	Healthy food product
US20090104335A1 (en) *	2006-03-24	2009-04-23	Yuguang Lin	Healthy Food Product
JP5592652B2 (ja) *	2007-02-05	2014-09-17	ナショナルユニバーシティオブシンガポール	推定サイトカイニン受容体およびその使用方法
US8097712B2 (en)	2007-11-07	2012-01-17	Beelogics Inc.	Compositions for conferring tolerance to viral disease in social insects, and the use thereof
WO2009113635A1 (ja) *	2008-03-12	2009-09-17	株式会社資生堂	不全角化抑制剤、毛穴縮小剤又は肌荒れ防止・改善剤及びそれを配合した皮膚外用組成物
CA2750462C (en) *	2009-02-06	2014-08-19	The Procter & Gamble Company	Collapsible water-containing capsules
CA2758200A1 (en) *	2009-04-10	2010-10-14	Abraxis Bioscience, Llc	Nanoparticle formulations and uses thereof
CA2758607C (en)	2009-05-04	2018-05-15	Psivida Us, Inc.	Porous silicon drug-eluting particles
US10555527B2 (en) *	2009-05-18	2020-02-11	Monsanto Technology Llc	Use of glyphosate for disease suppression and yield enhancement in soybean
GB0912481D0 (en) *	2009-07-17	2009-08-26	Reckitt Benckiser Healthcare I	Skincare compositions
US20110038910A1 (en)	2009-08-11	2011-02-17	Atrium Medical Corporation	Anti-infective antimicrobial-containing biomaterials
US8962584B2 (en)	2009-10-14	2015-02-24	Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd.	Compositions for controlling Varroa mites in bees
RU2012132445A (ru) *	2009-12-29	2014-02-10	У.Р. Грейс Энд Ко.-Конн.	Композиции для образования пленок, имеющих желательную степень матирования, и способы их получения и применения
CN102781404B (zh) *	2010-02-04	2014-08-27	Isp投资公司	用于无水遮光剂配制物的自适应聚合物
WO2011103247A2 (en) *	2010-02-18	2011-08-25	Athenix Corp.	Axmi218, axmi219, axmi220, axmi226, axmi227, axmi228, axmi229, axmi230, and axmi231 delta-endotoxin genes and methods for their use
CA3049609C (en) *	2010-02-18	2024-02-13	Athenix Corp.	Axmi221z, axmi222z, axmi223z, axmi224z, and axmi225z delta-endotoxin genes and methods for their use
HUE033056T2 (hu)	2010-03-08	2017-11-28	Monsanto Technology Llc	Polinukleotid molekulák génszabályozáshoz növényekben
FR2958155B1 (fr) *	2010-04-02	2012-04-20	Oreal	Composition de decoloration comprenant un sel peroxygene dans une base fortement riche en corps gras
WO2011137563A1 (en)	2010-05-07	2011-11-10	Unilever Plc	High solvent content emulsions
MX2012014066A (es) *	2010-06-04	2013-01-24	Monsanto Technology Llc	Evento de brassica transgenica mon 88302 y metodos para su uso.
WO2012009707A2 (en)	2010-07-16	2012-01-19	Atrium Medical Corporation	Composition and methods for altering the rate of hydrolysis of cured oil-based materials
CA2807171A1 (en) *	2010-08-19	2012-02-23	Pioneer Hi-Bred International, Inc.	Novel bacillus thuringiensis gene with lepidopteran activity
BR112013010190B1 (pt) *	2010-10-28	2019-12-31	Aequus Pharmaceuticals Inc	composição farmacêutica
US9757374B2 (en)	2010-10-28	2017-09-12	Aequus Pharmaceuticals Inc.	Aripiprazole compositions and methods for its transdermal delivery
JP6026424B2 (ja)	2010-11-01	2016-11-16	シヴィダ・ユーエス・インコーポレイテッドＰｓｉｖｉｄａＵｓ，Ｉｎｃ．	治療薬送達のための生物浸食性ケイ素ベースのデバイス
MX2013014098A (es) *	2011-06-04	2014-10-14	Texas A & M Univ Sys	Composiciones, sistemas, metodos, microorgnismos, y plantas de transformacion de patata.
BR112014002988A2 (pt) *	2011-08-12	2017-03-01	Bayer Cropscience Nv	expressão específica de célula de proteção de transgenes em algodão
MX361938B (es)	2011-09-13	2018-12-19	Monsanto Technology Llc	Métodos y composiciones para el control de malezas.
US9840715B1 (en)	2011-09-13	2017-12-12	Monsanto Technology Llc	Methods and compositions for delaying senescence and improving disease tolerance and yield in plants
US10760086B2 (en)	2011-09-13	2020-09-01	Monsanto Technology Llc	Methods and compositions for weed control
UY34328A (es)	2011-09-13	2013-04-30	Monsanto Technology Llc	?composiciones y métodos para controlar malezas comprendiendo un polinucleótido y agente de transferencia, y que modulan protoporfirinógeno ix oxidasa?.
US10829828B2 (en)	2011-09-13	2020-11-10	Monsanto Technology Llc	Methods and compositions for weed control
EP2755466A4 (en)	2011-09-13	2015-04-15	Monsanto Technology Llc	METHODS AND COMPOSITIONS FOR CONTROLLING WEEDS
CN104160028A (zh)	2011-09-13	2014-11-19	孟山都技术公司	用于杂草控制的方法和组合物
US10806146B2 (en)	2011-09-13	2020-10-20	Monsanto Technology Llc	Methods and compositions for weed control
US9920326B1 (en)	2011-09-14	2018-03-20	Monsanto Technology Llc	Methods and compositions for increasing invertase activity in plants
JP6188030B2 (ja) *	2011-10-05	2017-08-30	エフエムシーコーポレーションＦｍｃＣｏｒｐｏｒａｔｉｏｎ	微結晶セルロースおよびカルボキシメチルセルロースの安定化剤組成物、該組成物の製造方法並びに食品製品
US9492363B1 (en) *	2012-01-16	2016-11-15	American Spraytech, L.L.C.	Aerosol sprayable color composition
WO2013112806A2 (en) *	2012-01-27	2013-08-01	Agile Therapeutics, Inc.	Transdermal hormone delivery
FR2988566B1 (fr) *	2012-03-28	2014-08-08	Yoplait France	Compositions alimentaires pour stimuler la formation de tissu osseux
IN2014MN02404A (da)	2012-05-24	2015-08-21	Seeds Ltd Ab
ES2942682T3 (es) *	2012-08-03	2023-06-05	Msm Innovations Inc	Método y kit de preparación intestinal
CA2881685C (en)	2012-08-14	2023-12-05	10X Genomics, Inc.	Microcapsule compositions and methods
US10323279B2 (en)	2012-08-14	2019-06-18	10X Genomics, Inc.	Methods and systems for processing polynucleotides
US9701998B2 (en)	2012-12-14	2017-07-11	10X Genomics, Inc.	Methods and systems for processing polynucleotides
US9951386B2 (en)	2014-06-26	2018-04-24	10X Genomics, Inc.	Methods and systems for processing polynucleotides
US10752949B2 (en)	2012-08-14	2020-08-25	10X Genomics, Inc.	Methods and systems for processing polynucleotides
US10221442B2 (en)	2012-08-14	2019-03-05	10X Genomics, Inc.	Compositions and methods for sample processing
US10273541B2 (en)	2012-08-14	2019-04-30	10X Genomics, Inc.	Methods and systems for processing polynucleotides
US10584381B2 (en)	2012-08-14	2020-03-10	10X Genomics, Inc.	Methods and systems for processing polynucleotides
US11591637B2 (en)	2012-08-14	2023-02-28	10X Genomics, Inc.	Compositions and methods for sample processing
US9617297B2 (en) *	2012-10-11	2017-04-11	The Regents Of The University Of California	Apoplast wash fluid recovery for improved recombinant endoglucanase extraction in tabacco leaves
BR112015008706A2 (pt)	2012-10-18	2018-02-06	Monsanto Technology Llc	métodos e composições para controle de praga de plantas
EP2931919B1 (en)	2012-12-14	2019-02-20	10X Genomics, Inc.	Methods and systems for processing polynucleotides
US10533221B2 (en)	2012-12-14	2020-01-14	10X Genomics, Inc.	Methods and systems for processing polynucleotides
US9206436B2 (en) *	2012-12-20	2015-12-08	Ut-Battelle, Llc	Key gene regulating cell wall biosynthesis and recalcitrance in Populus, gene Y
UA118841C2 (uk)	2013-01-01	2019-03-25	Ей.Бі. СІДС ЛТД.	Спосіб формування рослини, яка має підвищену стійкість до комахи-шкідника
US10683505B2 (en)	2013-01-01	2020-06-16	Monsanto Technology Llc	Methods of introducing dsRNA to plant seeds for modulating gene expression
US10000767B2 (en)	2013-01-28	2018-06-19	Monsanto Technology Llc	Methods and compositions for plant pest control
KR20230003659A (ko)	2013-02-08	2023-01-06	10엑스 제노믹스, 인크.	폴리뉴클레오티드 바코드 생성
US8961680B2 (en) *	2013-03-08	2015-02-24	Tbf Environmental Technology Inc.	Solvent formulations
US20140271764A1 (en) *	2013-03-12	2014-09-18	Psivida Us, Inc.	Bioerodible Silicon-Based Delivery Vehicles for Delivery of Therapeutic Agents
CA2905104A1 (en)	2013-03-13	2014-10-09	Monsanto Technology Llc	Control of lolium species by topical application of herbicidal composition comprising dsrna
EP3604535A3 (en)	2013-03-13	2020-04-22	Monsanto Technology LLC	Methods and compositions for weed control
US20140283211A1 (en)	2013-03-14	2014-09-18	Monsanto Technology Llc	Methods and Compositions for Plant Pest Control
US9289461B2 (en)	2013-03-15	2016-03-22	Mead Johnson Nutrition Company	Reducing the risk of autoimmune disease
US9345741B2 (en)	2013-03-15	2016-05-24	Mead Johnson Nutrition Company	Nutritional composition containing a peptide component with adiponectin simulating properties and uses thereof
US9138455B2 (en)	2013-03-15	2015-09-22	Mead Johnson Nutrition Company	Activating adiponectin by casein hydrolysate
US9352020B2 (en)	2013-03-15	2016-05-31	Mead Johnson Nutrition Company	Reducing proinflammatory response
AU2014240095A1 (en) *	2013-03-15	2015-10-08	Maria Beug-Deeb Inc. Dba T&M Associates	Methods and compositions for cleaning and disinfecting surfaces
US8889633B2 (en)	2013-03-15	2014-11-18	Mead Johnson Nutrition Company	Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof
US9345727B2 (en)	2013-03-15	2016-05-24	Mead Johnson Nutrition Company	Nutritional compositions containing a peptide component and uses thereof
CA2904077A1 (en)	2013-03-15	2014-09-25	Psivida Us, Inc.	Bioerodible silicon-based compositions for delivery of therapeutic agents
US10568328B2 (en)	2013-03-15	2020-02-25	Monsanto Technology Llc	Methods and compositions for weed control
CA2817728A1 (en) *	2013-05-31	2014-11-30	Pharmascience Inc.	Abuse deterrent immediate release formulation
WO2015010026A2 (en)	2013-07-19	2015-01-22	Monsanto Technology Llc	Compositions and methods for controlling leptinotarsa
US9850496B2 (en)	2013-07-19	2017-12-26	Monsanto Technology Llc	Compositions and methods for controlling Leptinotarsa
HRP20221126T1 (hr) *	2013-10-07	2022-11-25	Bristol-Myers Squibb Holdings Ireland Unlimited Company	Formulacija atazanavira i kobicistata za liječenje hiv-a
WO2015066681A1 (en)	2013-11-04	2015-05-07	Monsanto Technology Llc	Compositions and methods for controlling arthropod parasite and pest infestations
UA119253C2 (uk)	2013-12-10	2019-05-27	Біолоджикс, Інк.	Спосіб боротьби із вірусом у кліща varroa та у бджіл
UA121462C2 (uk)	2014-01-15	2020-06-10	Монсанто Текнолоджі Елелсі	Спосіб та композиція для боротьби із бур'янами з використанням полінуклеотидів epsps
ES2544153B1 (es) *	2014-02-24	2016-06-06	Ntd Labs, S.L.	Uso de un hidrolizado de caseína como agente antiviral
BR112016022711A2 (pt)	2014-04-01	2017-10-31	Monsanto Technology Llc	composições e métodos para controle de pragas de inseto
WO2015157567A1 (en)	2014-04-10	2015-10-15	10X Genomics, Inc.	Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
EP3158067B1 (en)	2014-06-23	2020-08-12	Monsanto Technology LLC	Compositions and methods for regulating gene expression via rna interference
WO2015200539A1 (en)	2014-06-25	2015-12-30	Monsanto Technology Llc	Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression
WO2015200869A1 (en)	2014-06-26	2015-12-30	10X Genomics, Inc.	Analysis of nucleic acid sequences
AU2015279548B2 (en)	2014-06-26	2020-02-27	10X Genomics, Inc.	Methods of analyzing nucleic acids from individual cells or cell populations
EP3167049A4 (en)	2014-07-08	2017-11-29	MIMEDX Group Inc.	Micronized wharton's jelly
US20160022604A1 (en) *	2014-07-23	2016-01-28	Cadila Healthcare Limited	Directly compressed ospemifene compositions
AU2015296700B2 (en)	2014-07-29	2021-10-21	Monsanto Technology Llc	Compositions and methods for controlling insect pests
KR102305346B1 (ko) *	2014-09-11	2021-09-28	겔리타 아게	젤라틴/펙틴 입자
JP6943761B2 (ja) *	2014-09-17	2021-10-06	ロンザ，エルエルシー	活性化された過酸化水素消毒剤組成物
EP3212807B1 (en)	2014-10-29	2020-09-02	10X Genomics, Inc.	Methods and compositions for targeted nucleic acid sequencing
US9975122B2 (en)	2014-11-05	2018-05-22	10X Genomics, Inc.	Instrument systems for integrated sample processing
US10471096B2 (en) *	2015-01-06	2019-11-12	Osamu Yamada	Medicinal composition, blood treatment device, cosmetic, food and drink using combustion synthesis material
US10221436B2 (en)	2015-01-12	2019-03-05	10X Genomics, Inc.	Processes and systems for preparation of nucleic acid sequencing libraries and libraries prepared using same
US10968449B2 (en)	2015-01-22	2021-04-06	Monsanto Technology Llc	Compositions and methods for controlling Leptinotarsa
US10697000B2 (en)	2015-02-24	2020-06-30	10X Genomics, Inc.	Partition processing methods and systems
BR112017018054A2 (pt)	2015-02-24	2018-07-24	10X Genomics Inc	métodos para a cobertura de sequências de ácidos nucleicos direcionadas
WO2016137804A1 (en)	2015-02-25	2016-09-01	The Procter & Gamble Company	Fibrous structures comprising a surface softening composition
US20160303043A1 (en) *	2015-04-16	2016-10-20	Kate Somerville Skincare, LLC	Self-foaming compositions and methods
UY36703A (es)	2015-06-02	2016-12-30	Monsanto Technology Llc	Composiciones y métodos para la administración de un polinucleótido en una planta
EP3302030A4 (en)	2015-06-03	2019-04-24	Monsanto Technology LLC	METHODS AND COMPOSITIONS FOR THE INTRODUCTION OF NUCLEIC ACIDS IN PLANTS
WO2017011249A1 (en)	2015-07-10	2017-01-19	The Procter & Gamble Company	Fabric care composition comprising metathesized unsaturated polyol esters
CN115369161A (zh)	2015-12-04	2022-11-22	10X 基因组学有限公司	用于核酸分析的方法和组合物
WO2017197338A1 (en)	2016-05-13	2017-11-16	10X Genomics, Inc.	Microfluidic systems and methods of use
CN109328056A (zh)	2016-07-08	2019-02-12	吉列有限责任公司	用于毛发移除装置的包含复分解不饱和多元醇酯的液体组合物
DE102016223333A1 (de) *	2016-11-24	2018-05-24	Henkel Ag & Co. Kgaa	Alkalische Mittel zum Aufhellen von Haaren enthaltend Oxidationsmittel und spezielle Carbonsäureester als Keratinvernetzer
US10550429B2 (en)	2016-12-22	2020-02-04	10X Genomics, Inc.	Methods and systems for processing polynucleotides
US10011872B1 (en)	2016-12-22	2018-07-03	10X Genomics, Inc.	Methods and systems for processing polynucleotides
US10815525B2 (en)	2016-12-22	2020-10-27	10X Genomics, Inc.	Methods and systems for processing polynucleotides
WO2018140966A1 (en)	2017-01-30	2018-08-02	10X Genomics, Inc.	Methods and systems for droplet-based single cell barcoding
US12264411B2 (en)	2017-01-30	2025-04-01	10X Genomics, Inc.	Methods and systems for analysis
AU2018227842B2 (en) *	2017-03-01	2024-05-02	Arena Pharmaceuticals, Inc.	Compositions comprising PGI2-receptor agonists and processes for the preparation thereof
US10398670B2 (en) *	2017-04-24	2019-09-03	Knoze Jr. Corporation	Oral microbiota promotion for oral and/or sinus infections
CN109526228B (zh)	2017-05-26	2022-11-25	10X基因组学有限公司	转座酶可接近性染色质的单细胞分析
US20180340169A1 (en)	2017-05-26	2018-11-29	10X Genomics, Inc.	Single cell analysis of transposase accessible chromatin
US10471033B2 (en) *	2017-09-15	2019-11-12	Knoze Jr. Corporation	Oral microbiota promotion for immune system associated inflammations
US12151014B2 (en) *	2017-09-18	2024-11-26	Mast Industries (Far East) Limited	Gloss lip balm formulation
EP3954782A1 (en)	2017-11-15	2022-02-16	10X Genomics, Inc.	Functionalized gel beads
US10829815B2 (en)	2017-11-17	2020-11-10	10X Genomics, Inc.	Methods and systems for associating physical and genetic properties of biological particles
EP3775271B1 (en)	2018-04-06	2025-03-12	10X Genomics, Inc.	Systems and methods for quality control in single cell processing
US20220330599A1 (en) *	2019-09-16	2022-10-20	Kiverdi, Inc.	Microbial Protein Hydrolysate Compositions and Methods of Making Same

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3764670A (en) *	1970-10-28	1973-10-09	Ministry Of Agriculture	Polypeptidic anti-biotic substances derived from casein
US3778426A (en) *	1970-12-16	1973-12-11	Research Corp	Therapeutically useful polypeptides
US4636384A (en) *	1982-06-03	1987-01-13	Stolle Research & Development Corporation	Method for treating disorders of the vascular and pulmonary systems
US4959455A (en) *	1986-07-14	1990-09-25	Genetics Institute, Inc.	Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5344820A (en) *	1987-05-15	1994-09-06	Snow Brand Milk Products Co., Ltd.	Infection protectant
JP2631470B2 (ja) *	1987-05-15	1997-07-16	雪印乳業株式会社	感染防御剤
JP2805490B2 (ja) *	1989-02-07	1998-09-30	雪印乳業株式会社	細菌毒素中和剤
US5514646A (en) *	1989-02-09	1996-05-07	Chance; Ronald E.	Insulin analogs modified at position 29 of the B chain
FR2686085B1 (fr) *	1992-01-10	1995-08-04	Agronomique Inst Nat Rech	Peptides representant des fragments du cmp, anticorps diriges contre lesdits peptides, et leurs utilisations.
GB9310472D0 (en) *	1993-05-20	1993-07-07	Univ Warwick	Phenylalanine-free protein and dna coding thereof
TW282398B (da) *	1993-12-22	1996-08-01	Bristol Myers Squibb Co
US5506209A (en) *	1994-05-26	1996-04-09	Abbott Laboratories	Product for inhibition of infection of mammalian cells by respiratory syncytial virus
US5707968A (en) *	1994-05-26	1998-01-13	Abbott Laboratories	Inhibition of attachment of H.influenzae to human cells
US5538952A (en) *	1994-05-26	1996-07-23	Abbott Laboratories	Inhibition of infection of mammalian cells by respiratory syncytial virus
US5712250A (en) *	1994-09-16	1998-01-27	Abbott Laboratories	Product for inhibition of human rotavirus infection
KR0140248B1 (ko) *	1995-03-23	1998-06-15	한상기	신규한 카제인 포스포펩티드, 그것을 포함하는 카제인 및 그 제조방법
US5985275A (en) *	1995-04-12	1999-11-16	New York Blood Center	β-Lactoglobulin modified with aromatic anhydride compound for preventing HIV infection
US6570060B2 (en) *	1995-05-16	2003-05-27	Mclachlan Corran Norman Stuart	Milk lacking β-casein A1
KR100221124B1 (ko) *	1996-09-23	1999-10-01	한상기	신규한 카제인 및 그 제조방법
US5830434A (en) *	1997-02-26	1998-11-03	Medical University Of South Carolina Foundation For Research Development	Methods of treating non-insulin dependent diabetes mellitus with pancreatic polypeptide
NZ332993A (en) *	1997-03-21	2000-01-28	Snow Brand Milk Products Co Ltd	Iron-casein complex hydrolyzate and process for the production thereof
US6358508B1 (en) *	1997-06-11	2002-03-19	Human Genome Sciences, Inc.	Antibodies to human tumor necrosis factor receptor TR9
EP0996726B1 (en) *	1997-08-29	2003-12-10	Brigham And Women's Hospital	T-cell membrane protein (tirc7), peptides and antibodies derived therefrom and uses thereof
AUPP051497A0 (en) *	1997-11-24	1997-12-18	University Of Melbourne, The	Antimicrobial peptides
US5985575A (en) *	1998-05-20	1999-11-16	Wisconsin Alumni Research Foundation	Tethered function assay for protein function
US6570606B1 (en) *	1998-05-29	2003-05-27	3Com Corporation	Method and apparatus for controlling transmission of media signals over a data network in response to triggering events at participating stations
AU2150900A (en) *	1998-11-16	2000-06-05	Board Of Regents, The University Of Texas System	Hiv-specific t-cell induction
GB9927603D0 (en) *	1999-11-22	2000-01-19	Nestle Sa	Use of a milk protein hydrolysate in the treatment of diabetes
IL138946A0 (en) *	2000-10-11	2001-11-25	Compugen Ltd	Method for the identification of peptides and proteins
AU2006296991A1 (en) *	2005-09-28	2007-04-05	Dnp Canada Inc.	Combination of polychitosamine and fibrate for the prevention and treatment of hyperlipidemia
US8865876B2 (en) *	2008-06-02	2014-10-21	California Institute Of Technology	Engineered lectin oligomers with antiviral activity

2000
- 2000-03-01 IL IL13483000A patent/IL134830A0/xx unknown
2001
- 2001-03-01 JP JP2001563131A patent/JP2003528827A/ja active Pending
- 2001-03-01 DE DE60140794T patent/DE60140794D1/de not_active Expired - Lifetime
- 2001-03-01 EA EA200200820A patent/EA005579B1/ru not_active IP Right Cessation
- 2001-03-01 NZ NZ521016A patent/NZ521016A/en unknown
- 2001-03-01 AU AU35962/01A patent/AU782662B2/en not_active Ceased
- 2001-03-01 BR BR0109027-5A patent/BR0109027A/pt not_active IP Right Cessation
- 2001-03-01 CN CN01808959A patent/CN1427725A/zh active Pending
- 2001-03-01 MX MXPA02008569A patent/MXPA02008569A/es not_active Application Discontinuation
- 2001-03-01 EA EA200401467A patent/EA007217B1/ru not_active IP Right Cessation
- 2001-03-01 WO PCT/IL2001/000198 patent/WO2001064234A1/en active IP Right Grant
- 2001-03-01 DK DK01908105.8T patent/DK1261360T3/da active
- 2001-03-01 PL PL36130701A patent/PL361307A1/xx unknown
- 2001-03-01 HU HU0301003A patent/HUP0301003A3/hu unknown
- 2001-03-01 AT AT01908105T patent/ATE451929T1/de not_active IP Right Cessation
- 2001-03-01 EP EP01908105A patent/EP1261360B1/en not_active Expired - Lifetime
- 2001-03-01 CZ CZ20022915A patent/CZ20022915A3/cs unknown
- 2001-03-01 CA CA002401550A patent/CA2401550A1/en not_active Abandoned
- 2001-08-30 US US09/942,121 patent/US20020147144A1/en not_active Abandoned
2002
- 2002-08-19 IL IL151351A patent/IL151351A/en active IP Right Grant
- 2002-08-27 ZA ZA200206842A patent/ZA200206842B/en unknown
- 2002-08-29 EA EA200400376A patent/EA007814B1/ru not_active IP Right Cessation
- 2002-08-30 NO NO20024157A patent/NO20024157L/no not_active Application Discontinuation
- 2002-08-31 KR KR10-2002-7011450A patent/KR20030025907A/ko active Pending
2006
- 2006-09-08 US US11/518,400 patent/US7741274B2/en not_active Expired - Lifetime
2007
- 2007-10-31 US US11/982,369 patent/US20090192081A1/en not_active Abandoned
2010
- 2010-04-22 US US12/764,996 patent/US20100298216A1/en not_active Abandoned
- 2010-07-28 US US12/844,834 patent/US20100317601A1/en not_active Abandoned
2012
- 2012-09-05 US US13/603,428 patent/US8735348B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US8735348B2 (en)	2014-05-27
MXPA02008569A (es)	2003-02-24
EA200400376A1 (ru)	2005-06-30
KR20030025907A (ko)	2003-03-29
EA007217B1 (ru)	2006-08-25
EP1261360A4 (en)	2004-03-10
CZ20022915A3 (cs)	2003-03-12
CA2401550A1 (en)	2001-09-07
EP1261360B1 (en)	2009-12-16
WO2001064234A1 (en)	2001-09-07
EP1261360A1 (en)	2002-12-04
CN1427725A (zh)	2003-07-02
NO20024157D0 (no)	2002-08-30
HUP0301003A3 (en)	2007-08-28
JP2003528827A (ja)	2003-09-30
US20130096073A1 (en)	2013-04-18
US20100298216A1 (en)	2010-11-25
HUP0301003A2 (hu)	2003-07-28
US20070161557A1 (en)	2007-07-12
EA200401467A1 (ru)	2005-04-28
EA005579B1 (ru)	2005-04-28
EA007814B1 (ru)	2007-02-27
IL134830A0 (en)	2001-05-20
US20020147144A1 (en)	2002-10-10
DE60140794D1 (de)	2010-01-28
NZ521016A (en)	2005-08-26
ZA200206842B (en)	2003-07-28
US7741274B2 (en)	2010-06-22
IL151351A (en)	2012-04-30
EA200200820A1 (ru)	2003-08-28
ATE451929T1 (de)	2010-01-15
US20100317601A1 (en)	2010-12-16
US20090192081A1 (en)	2009-07-30
AU3596201A (en)	2001-09-12
AU782662B2 (en)	2005-08-18
PL361307A1 (en)	2004-10-04
BR0109027A (pt)	2003-06-03
NO20024157L (no)	2002-10-30

Publication	Publication Date	Title
DK1261360T3 (da)	2010-05-03	Casein-afledte peptider og anvendelser deraf i behandling
WO2005081628A3 (en)	2007-10-18	Casein derived peptides and therapeutic uses thereof
ATE486614T1 (de)	2010-11-15	Zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie
ES2187798T3 (es)	2003-06-16	Procedimiento de conservacion de virus recombinantes infecciosos, suspension acuosa viral y su utilizacion como medicamento.
DE69838986D1 (de)	2008-02-21	Polypeptide, deren herstellung und verwendung
TR200102308T2 (tr)	2002-04-22	Yüzey etkinliğine sahip yapay peptidler ve bunların yapay yüzey aktif maddelerin hazırlanmasında kullanımı
ECSP093601A (es)	2009-08-28	Proteínas derivadas del virus del síndrome de mancha blanca y sus usos
WO2002086100A3 (en)	2004-02-19	Expression of core-glycosylated hcv envelope proteins in yeast
PL375113A1 (en)	2005-11-28	Casein derived peptides and uses thereof in therapy
DK0750672T3 (da)	2002-03-18	DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
DE69719754D1 (de)	2003-04-17	Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
ATE374618T1 (de)	2007-10-15	Verwendung von rekombinanten menschlichen uteroglobin zur behandlung von fibrotischen krankheitszuständen
ATE375786T1 (de)	2007-11-15	Chitin-mikropartikel und ihre medizinische verwendung
NZ508505A (en)	2003-04-29	Treatment of wounds using an Egr-1 transcription factor polypeptide
FR2870126A1 (fr)	2005-11-18	Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
NO971247L (no)	1997-03-18	Defektive, rekombinante adenoviruser med inaktivt IVa2-gen
EP1222255A4 (en)	2004-03-31	POLYPEPTIDE FRAGMENTS COMPRISING A C-TERMINAL PART OF HELICOBACTER CATALASE
WO2001045738A3 (en)	2001-12-27	Use of heat shock proteins to enhance production of chemokines by a cell
ATE62789T1 (de)	1991-05-15	Mittel zur bekaempfung von phytopathogenen mikroben.
ATE544453T1 (de)	2012-02-15	Kombinationstherapien mit l-fmau zur behandlung von hepatitis-b-virus-infektionen
ATE386542T1 (de)	2008-03-15	Mittel zur stimulation des immunsystems
DK1250422T3 (da)	2006-05-29	Myeloid-kolonistimulerende faktor og anvendelser deraf
ATE383866T1 (de)	2008-02-15	Antiproliferative und antivirale proteine und peptide
ATE275984T1 (de)	2004-10-15	Biokompatible kolloide mit geringer zelladhäsion und aktiver stabilisierung von blutproteinen